These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30533654)

  • 41. Detection of bla
    Balero de Paula S; Cayô R; Streling AP; Silva Nodari C; Pereira Matos A; Eches Perugini MR; Gales AC; Carrara-Marroni FE; Yamada-Ogatta SF
    Diagn Microbiol Infect Dis; 2017 Sep; 89(1):80-82. PubMed ID: 28669677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis.
    Lim CLL; Chua AQ; Teo JQM; Cai Y; Lee W; Kwa AL
    Int J Infect Dis; 2018 Nov; 76():48-57. PubMed ID: 29870795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two Novel Bacteriophages Improve Survival in
    Jeon J; Yong D
    Appl Environ Microbiol; 2019 May; 85(9):. PubMed ID: 30824445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates.
    Lee H; Roh KH; Hong SG; Shin HB; Jeong SH; Song W; Uh Y; Yong D; Lee K
    Ann Lab Med; 2016 Mar; 36(2):138-44. PubMed ID: 26709261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.
    Sánchez-Diener I; Zamorano L; López-Causapé C; Cabot G; Mulet X; Peña C; Del Campo R; Cantón R; Doménech-Sánchez A; Martínez-Martínez L; Arcos SC; Navas A; Oliver A
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multidrug and extensive drug resistance in Pseudomonas aeruginosa clinical isolates from a Portuguese central hospital: 10-year survey.
    Pereira SG; Marques M; Pereira J; Cardoso O
    Microb Drug Resist; 2015 Apr; 21(2):194-200. PubMed ID: 25372011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt.
    Hasanin A; Eladawy A; Mohamed H; Salah Y; Lotfy A; Mostafa H; Ghaith D; Mukhtar A
    Pan Afr Med J; 2014; 19():177. PubMed ID: 25815098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole genome sequencing uncovers a novel IND-16 metallo-β-lactamase from an extensively drug-resistant
    Wang T; Jiang X; Feng C; Li A; Dong H; Wu S; Zheng B
    Gut Pathog; 2016; 8():47. PubMed ID: 27785154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative genome and transcriptome analysis reveals distinctive surface characteristics and unique physiological potentials of Pseudomonas aeruginosa ATCC 27853.
    Cao H; Lai Y; Bougouffa S; Xu Z; Yan A
    BMC Genomics; 2017 Jun; 18(1):459. PubMed ID: 28606056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Draft Genome Sequence of Pseudomonas aeruginosa Strain PA14-UM.
    Lee VT; Ghodssi R; El-Sayed NM; Malik RD; Goloubeva OG; Hazen TH; Rasko DA
    Microbiol Resour Announc; 2020 Nov; 9(46):. PubMed ID: 33184157
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of clinical extensively drug resistant Pseudomonas aeruginosa from a Chinese teaching hospital.
    Zou M; Wang H; Shui J; Li J; Hu Y; Dou Q; Yan Q; Liu WE
    J Infect Dev Ctries; 2018 Oct; 12(10):835-841. PubMed ID: 32004151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.
    Horcajada JP; Montero M; Oliver A; Sorlí L; Luque S; Gómez-Zorrilla S; Benito N; Grau S
    Clin Microbiol Rev; 2019 Sep; 32(4):. PubMed ID: 31462403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Draft Genome Sequence of a Pseudomonas aeruginosa Strain Able To Decompose N,N-Dimethyl Formamide.
    Yan L; Yan M; Xu L; Wei L; Zhang L
    Genome Announc; 2016 Feb; 4(1):. PubMed ID: 26847883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complete Genome Sequence of Pseudomonas aeruginosa K34-7, a Carbapenem-Resistant Isolate of the High-Risk Sequence Type 233.
    Taiaroa G; Samuelsen Ø; Kristensen T; Økstad OAL; Heikal A
    Microbiol Resour Announc; 2018 Aug; 7(4):. PubMed ID: 30533874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Draft Genome Sequence of an Extensively Drug-Resistant Acinetobacter baumannii Indigo-Pigmented Strain.
    Traglia G; Vilacoba E; Almuzara M; Diana L; Iriarte A; Centrón D; Ramírez MS
    Genome Announc; 2014 Nov; 2(6):. PubMed ID: 25395633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.